The underlying beneficial effects likely go beyond erythropoiesis and include counteraction of the complex pathophysiology of COVID-19 as delineated in the present paper and previous reviews on EPO in COVID-19 (Ehrenreich et al. 2020; Sahebnasagh et al. 2020). This evidence concerns the gene EPO and COVID-19.